Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child–Pugh classification B: A retrospective observational study

The therapeutic effect of regorafenib was previously demonstrated in patients with advanced hepatocellular carcinoma (HCC) and Child–Pugh classification A (CP-A) whose disease progressed during sorafenib treatment in a phase III trial. However, treatment options are limited for patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Komiyama, Satoshi, Numata, Kazushi, Ogushi, Katsuaki, Moriya, Satoshi, Fukuda, Hiroyuki, Chuma, Makoto, Maeda, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373530/
https://www.ncbi.nlm.nih.gov/pubmed/32702881
http://dx.doi.org/10.1097/MD.0000000000021191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373530/
https://www.ncbi.nlm.nih.gov/pubmed/32702881
http://dx.doi.org/10.1097/MD.0000000000021191

Ejemplares similares